Fresenius (company)
| Company type | Kommanditgesellschaft auf Aktien with Societas Europaea as partner with unlimited liability |
|---|---|
| ISIN | DE0005785604 |
| Industry | Health care |
| Founded | 1912 |
| Founder | Eduard Fresenius |
| Headquarters | Bad Homburg vor der Höhe, Germany |
Key people | Michael Sen (CEO and chairman of the management board) Wolfgang Kirsch (Chairman of the supervisory board) |
| Products | infusion pumps, medication, hospitals, medical care |
| Services | Dialysis |
| Revenue | €22.3 billion (2023) |
| €2.26 billion (2023) | |
| €1.51 billion (2023) | |
| Total assets | €45.3 billion (2023) |
| Total equity | €19.7 billion (2023) |
| Owner | Else Kröner-Fresenius Foundation (26.6%) |
Number of employees | 193,865 (2023) |
| Website | www |
Fresenius SE & Co. KGaA is a German multinational health care company based in Bad Homburg vor der Höhe. It provides products and services for dialysis in hospitals, as well as inpatient and outpatient medical care. The company is involved in hospital management and in engineering and services for medical centers and other health care facilities.
The company is ranked 411th in the Forbes Global 2000 list in 2023.
In March 2022, it announced plans to merge with InterWell Health and Cricket Health to form a new company, which will operate under the InterWell Health brand, focused on services for the earlier stages of kidney disease.